EIGRQ Stock - Eiger BioPharmaceuticals, Inc.
Unlock GoAI Insights for EIGRQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $15.77M | $13.48M | $12.14M | N/A | N/A |
| Gross Profit | $15.00M | $10.80M | $10.60M | $-645,000 | $-486,000 |
| Gross Margin | 95.1% | 80.1% | 87.3% | N/A | N/A |
| Operating Income | $-71,786,000 | $-92,740,000 | $-76,939,000 | $-62,149,000 | $-68,904,000 |
| Net Income | $-74,963,000 | $-96,776,000 | $-33,917,000 | $-65,051,000 | $-70,252,000 |
| Net Margin | -475.3% | -717.7% | -279.3% | N/A | N/A |
| EPS | $-50.78 | $-69.74 | $-29.98 | $-69.34 | $-92.50 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
Visit WebsiteEarnings History & Surprises
EIGRQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 7, 2025 | — | — | — | — |
Q4 2024 | Nov 7, 2024 | — | — | — | — |
Q4 2024 | Oct 2, 2024 | $-3.30 | — | — | — |
Q2 2024 | Apr 8, 2024 | $-7.50 | $-49.39 | -558.5% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-7.50 | $-49.39 | -558.5% | ✗ MISS |
Q4 2023 | Dec 28, 2023 | $-9.71 | $-12.30 | -26.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-11.70 | $-14.02 | -19.8% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-13.59 | $-15.48 | -14.0% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-15.90 | $-17.11 | -7.6% | ✗ MISS |
Q3 2022 | Sep 29, 2022 | $-15.16 | $-18.48 | -21.9% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | — | $-15.25 | — | — |
Q1 2022 | Mar 30, 2022 | $-17.45 | $-19.27 | -10.4% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $-19.20 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-19.64 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-16.95 | — | — |
Latest News
Frequently Asked Questions about EIGRQ
What is EIGRQ's current stock price?
What is the analyst price target for EIGRQ?
What sector is Eiger BioPharmaceuticals, Inc. in?
What is EIGRQ's market cap?
Does EIGRQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EIGRQ for comparison